[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331224-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331224-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","serum-tlr2-and-tlr9-in-prostate-cancer-patients-in-relation-to-ebv-status","Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status","","The relationship between Toll-like receptors (TLRs) and prostate cancer (PCa) is complex because Epstein–Barr virus (EBV) infection is linked to cancer susceptibility. This study examined serum from PCa patients to clarify these interactions by measuring selected TLR levels and assessing the possible impact of EBV infection on PCa characteristics. EBV(+) patients were compared across risk groups and clinical parameters including Gleason score and T-traits, and correlations between TLR and antibody levels were evaluated. Higher TLR-2 and TLR-9 levels were observed in more advanced disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/serum-tlr2-and-tlr9-in-prostate-cancer-patients-in-relation-to-ebv-status/331224/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/serum-tlr2-and-tlr9-in-prostate-cancer-patients-in-relation-to-ebv-status/331224.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the study on TLRs and EBV in prostate cancer?","Question",{"text":63,"@type":64},"To investigate the complex links between Toll-like receptors and prostate cancer in the context of Epstein–Barr virus infection by examining serum TLR levels and the potential impact of EBV on PCa.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers compare EBV(+) patients?",{"text":68,"@type":64},"EBV(+) patients were compared across risk groups and clinical parameters, including Gleason score and T-traits.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding TLR-2 and TLR-9?",{"text":72,"@type":64},"Higher levels of TLR-2 and TLR-9 were detected in patients with more advanced prostate cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331224,1790462646,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nSerum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status  \nDominika Sikora 1, *, Jacek Ki´s 2, Ewa St˛epie ´n 1, Bartłomiej Drop 3 and Małgorzata Polz-Dacewicz 1  \nCitation: Sikora, D.; Ki´s, J.; St˛epie ´n, E.; Drop, B.; Polz-Dacewicz, M. Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status. Int.  \nJ. Mol. Sci. 2024, 25, 9053. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25169053](doi.org/10.3390/ijms25169053)  \nAcademic Editor: Hiroshi Miyamoto  \nReceived: 20 June 2024  \nRevised: 16 August 2024  \nAccepted: 20 August 2024  \nPublished: 21 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Virology with Viral Diagnostics Laboratory, Medical University of Lublin, 20-093 Lublin, Poland; [ewa.stepien@umlub.pl](ewa.stepien@umlub.pl) (E.S.); [malgorzata.polz-dacewicz@umlub.pl](malgorzata.polz-dacewicz@umlub.pl) (M.P.-D.)  \n2 1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, Poland; [jacekkis@gmail.com](jacekkis@gmail.com)  \n[3](3 Department of Medical Informatics and Statistics with e-Health Lab)[ Department of Medical Informatics and Statistics with e-Health Lab](3 Department of Medical Informatics and Statistics with e-Health Lab), [Medical University of Lublin](Medical University of Lublin), 20-090 Lublin, Poland; [bartlomiej.drop@umlub.pl](bartlomiej.drop@umlub.pl)  \n* Correspondence: [dominika.sikora@umlub.pl](dominika.sikora@umlub.pl)  \nAbstract: The relationship between Toll-like receptors (TLRs) and prostate cancer (PCa) is complex due to the presence of the Epstein–Barr virus (EBV) infection, which has been identified as a predisposing factor for some cancers, including PCa. The present study aims to investigate these complex links by examining the levels of selected TLRs and the potential impact of EBV infection on PCa. Therefore, we examined the serum of patients with PCa. The study compared EBV(+) patients to risk groups, the Gleason score (GS), and the T-trait. Additionally, the correlation between TLR and antibody levels was examined. The results indicated that higher levels of TLR-2 and TLR-9 were observed in more advanced PCa. The findings of this study may contribute to a deeper understanding of the role of viral infections in PCa and provide information on future strategies for the diagnosis, prevention, and treatment of these malignancies.  \nKeywords: prostate cancer; Epstein–Barr virus; TLR-2; TLR-9  \n1. Introduction  \nProstate cancer (PCa) is an important global health issue. A total of 1,465,854 men were diagnosed with it in 2022 . This represents a substantial increase from the previous year [1,2] . According to the World Health Organization (WHO), it is the fifth leading cause of cancer-related mortality worldwide. In Poland, the incidence of this type of cancer is increasing, and the Ministry of Health and the National Health Fund forecasts that this trend will continue. In Poland, approximately 15,000 men are diagnosed with PCa each year, and it is expected that this number will soon reach approximately 20,000 men per year [3] .  \nPCa usually begins in the peripheral part of the prostate. PCa is often initially asymptomatic, and the symptoms resemble benign organ hyperplasia. Prostate issues may result in a sudden urge to urinate, frequent urination, a burning sensation upon urination, ora sensation that the urine has not been fully expelled. Its aggressive nature and asymptomatic early stage make it a severe problem requiring attention and intervention [4] . When invasive cancer infiltrates the surrounding tissues and organs, it spreads through the blood and lymphatic vessels, often metas","cbCaipUg5CqTsoAf","https://ap.wps.com/l/cbCaipUg5CqTsoAf","pdf",5275376,15,"English","# Abstract\n# Introduction","[{\"question\":\"What was the main purpose of the study on TLRs and EBV in prostate cancer?\",\"answer\":\"To investigate the complex links between Toll-like receptors and prostate cancer in the context of Epstein–Barr virus infection by examining serum TLR levels and the potential impact of EBV on PCa.\"},{\"question\":\"How did the researchers compare EBV(+) patients?\",\"answer\":\"EBV(+) patients were compared across risk groups and clinical parameters, including Gleason score and T-traits.\"},{\"question\":\"What were the key findings regarding TLR-2 and TLR-9?\",\"answer\":\"Higher levels of TLR-2 and TLR-9 were detected in patients with more advanced prostate cancer.\"}]","Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status | PDF",1789992302,38]